{"filing":{"accession_number":"0001357459-26-000017","cik":"0001357459","ticker":"PALI","company_name":"PALISADE BIO, INC.","form":"8-K","filing_date":"2026-08-10","report_date":"2026-08-10","primary_document":"pali-20260810.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1357459/000135745926000017/pali-20260810.htm"},"events":[{"id":26619,"run_id":24199,"accession_number":"0001357459-26-000017","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"Palisade Bio issued a press release on August 10, 2026 announcing financial results for the three and six months ended June 30, 2026, including condensed consolidated balance sheets, statements of operations, and cash flow statements. The disclosure includes key financial metrics (net loss of $10.6 million for Q2 2026 vs. $2.8 million for Q2 2025, cash position of $125.2 million) and material operational updates on PALI-2108 Phase 2 development progress. This is a standard earnings release disclosure under Item 2.02.","company_name":"PALISADE BIO, INC.","ticker":"PALI","filing_date":"2026-08-10","form":"8-K","submitted_at":null,"items":[{"id":27811,"accession_number":"0001357459-26-000017","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Palisade Bio issued a press release on August 10, 2026 announcing financial results for the three and six months ended June 30, 2026, including condensed consolidated balance sheets, statements of operations, and cash flow statements. The disclosure includes key financial metrics (net loss of $10.6 million for Q2 2026 vs. $2.8 million for Q2 2025, cash position of $125.2 million) and material operational updates on PALI-2108 Phase 2 development progress. This is a standard earnings release disclosure under Item 2.02.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-10T20:29:46.163553+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":27811,"accession_number":"0001357459-26-000017","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Palisade Bio issued a press release on August 10, 2026 announcing financial results for the three and six months ended June 30, 2026, including condensed consolidated balance sheets, statements of operations, and cash flow statements. The disclosure includes key financial metrics (net loss of $10.6 million for Q2 2026 vs. $2.8 million for Q2 2025, cash position of $125.2 million) and material operational updates on PALI-2108 Phase 2 development progress. This is a standard earnings release disclosure under Item 2.02.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-10T20:29:46.163553+00:00","company_name":"PALISADE BIO, INC.","ticker":"PALI","filing_date":"2026-08-10"}]}